The company has seen a reduction of sales in 2 years from generating nearly $4 billion to $12 million. Logo credit: AstraZenecaAstraZeneca is removing its COVID-19 vaccine, Vaxzevria, from the market, according to a report on CNN. The company cited low sales for its removal.1The vaccine was not authorized or approved in the United States and sales had been lagging globally. According to AstraZeneca, Sipavibart was designed to provide broad and potent coverage across Omicron and ancestral viral variants by neutralizing spike protein interaction with the host receptor ACE2.3ReferencesZiady H. AstraZeneca withdraws Covid-19 vaccine, citing low demand. Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]).

Source: CNN May 09, 2024 17:54 UTC